Ensitrelvir Fumaric Acid

N/A

Report date: 2023/04/06 09:34:20
NME

Base Information

Drug NameEnsitrelvir Fumaric Acid
Drug Alias NameEnsitrelvirXocovaS-217622
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeRenal Insufficiency +[4] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/11/22
Country/TerritoryUnited StatesUkraineVietnam +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesShionogi & Co LtdHokkaido University
China Registration ClassN/A

Develop Information

Active CompaniesMedicines Patent PoolIldong Pharmaceutical Co LtdShionogi Inc +[5] 
Inactive CompaniesUniversity Of Minnesota
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeRenal Insufficiency +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A